# Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

> **NCT06555133** · PHASE2 · RECRUITING · sponsor: **Brown University** · enrollment: 18 (estimated)

## Conditions studied

- Colorectal Carcinoma Metastatic in the Liver

## Interventions

- **COMBINATION_PRODUCT:** yttrium-90 radioembolization

## Key facts

- **NCT ID:** NCT06555133
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2026-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06555133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06555133, "Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06555133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*